Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,640.45 -1,718.98 (-2.76%) CMC Crypto 200
1,257.21 -100.80 (-7.42%)
United Therapeutics Corporation (UTHR)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:30PM EDT. Market open.
| Previous close | 266.05 |
| Open | 266.00 |
| Bid | 264.50 x 100 |
| Ask | 265.07 x 100 |
| Day's range | 264.27 - 269.81 |
| 52-week range | 204.44 - 269.81 |
| Volume | |
| Avg. volume | 530,333 |
| Market cap | 11.734B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 12.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
- Zacks
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
- Zacks
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
© 2024 Yahoo. All rights reserved.